Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Big Pharma Comes to Retina
Four major deals in eighteen months: Merck/EyeBio (up to $3B, 2024), Eli Lilly/Adverum Biotechnologies (up to $262M, 2025), Biogen/Apellis ($5.6B, 2026), AbbVie/Regenxbio licensing partnership (up to $1.75B). Only Apellis had an approved drug at time of acquisition.
The gold rush is not over. Kodiak Sciences, with a multi-indication BLA in Q4 2026, is a prime target. EyeBio founders David R. Guyer, MD, and Tony Adamis, MD, co-founders of Eyetech and the first approved anti-VEGF, are now at Merck with remigromig and tiespectus in the pipeline.
BRUNELLO Deep Dive with Donald J. D'Amico, MD
Study recap: remigromig 0.5 mg and 0.8 mg monthly vs. ranibizumab 0.5 mg in DME. 25% were previously treated, and both doses met non-inferiority on BCVA change at week 52.
The Wnt pathway: remigromig activates FZD4 and two LRP5 epitopes simultaneously via a tetravalent, trispecific antibody that mimics norrin, the natural Wnt agonist in retinal vasculature. The pathway has stymied pharmacologists for decades.
The PDR signal: 6.1-6.7% in remigromig arms vs. 0.9% with ranibizumab. The signal is permissive, not causative. RISE/RIDE sham controls showed 16.3% PDR at year one, and VIVID/VISTA showed 11.1% at year two. Remigromig patients compare favorably to natural history.
Why ranibizumab 0.5 mg: the only active comparator with an established non-inferiority margin and a primarily monthly dosing label. The 0.5 mg dose reflects international standard, and the trial targets global approval.
Duration unknown: remigromig was dosed monthly in BRUNELLO, but effect duration is unstudied. Dr. D'Amico raises the possibility of three loading doses producing months of benefit. Combination with anti-VEGF is the logical next step. BAROLO companion study expected Q1-Q2 2027.
RetinUp Year One
Laura Brown: came in knowing nothing about retina and hopes to record live at a future meeting (specifically, Hawaii).
Liz Hogan: surprised by industry partners' warmth, and notes breaking news episodes turned around in under 12 hours are an industry best.
John Kitchens, MD: proud of editorial independence and breaking news speed, and wants weekly episodes and more human interest storytelling.
Scott Krzywonos: credits the whole team and John's years of genuine win-win relationship building with industry.
Key Takeaways
The retina acquisition wave is not over. Kodiak and others remain attractive targets as the pipeline continues to mature.
Remigromig's PDR signal is permissive, not causative. Cross-trial data suggest remigromig patients fare better than natural history controls.
Year one of RetinUp: 4,786+ downloads, a year of breaking news, and a field that produced more clinical data in twelve months than most specialties see in a decade.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube